The University of Oxford on Thursday said its COVID-19 vaccine candidate has a better immune response when a full two-dose regimen is used rather than a full-dose followed by a half-dose booster, Reuters reported. The Oxford vaccine candidate, licensed to AstraZeneca, has published the results of late-stage interim studies showing greater efficacy when a half dose is followed by a full dose, compared to a full two-dose regimen, although it is more work must be done to affirm the result.
On Thursday, details of Phase I / II clinical trials were released, which did not refer to the half-dose / full-dose regimen, which Oxford said was “not planned” but approved by regulators. The university said it explored two dosing regimens in the early trial stages, a full-dose / full-dose regimen and a full-dose / half-dose regimen, studied as a possible ‘dose reduction’ strategy.
“Booster doses of the vaccine have both been shown to induce stronger antibody responses than a single dose, the standard dose / standard dose that induces the best response,” the university said in a statement.
The vaccine “stimulates extensive antibody and T cell functions,” he said further.
Previously, Oxford University researchers and major pharmaceutical company AstraZeneca presented a pooled analysis of their COVID-19 vaccine phase 3 studies across two different dosing regimens, which demonstrated that the vaccine is safe and has an average effectiveness of 70.4%.
When the results of the interim study were made public in a press release last month, the researchers reported three levels of effectiveness for the vaccine: an overall effectiveness of 70 percent, a lower one of 62 percent, and a high of 90 percent. at different doses of the vaccine incorrectly used in one part of the trial.
The COVID-19 vaccine from the University of Oxford and AstraZeneca, currently awaiting regulatory approval, will be used for a “mix and match” trial with the Russian Sputnik vaccine against the new coronavirus.
READ ALSO | FDA will swiftly clear second Covid-19 vaccine after key panel pushed Moderna emergency approval
Meanwhile, AstraZeneca country president Gagandeep Singh said the Oxford-AstraZeneca vaccine may be available in India as early as the first half of 2021. The Pune-based Serum Institute of India is conducting clinical trials on the COVID vaccine -19, candidate at the University of Oxford, Covishield, in AstraZeneca. India.
According to Singh, the vaccine can be stored, transported and handled in comfortable refrigerated conditions (2 to 8 degrees), which is very convenient to handle, meaning it can be administered very quickly across the country.